Navigation Links
Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease
Date:4/12/2011

HONOLULU, April 12, 2011 /PRNewswire-USNewswire/ -- Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9–16, 2011, in Honolulu.

"Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," said study author Ravi Anand, MD, a consultant with Newron Pharmaceuticals in Bresso, Italy. "These results are an important step forward in understanding how safinamide impacts patients with severe Parkinson's disease. Symptoms of Parkinson's disease, motor fluctuations and dyskinesia can greatly affect a person's daily living and quality of life."

For the two-year study, 669 patients with mid-to-late stage Parkinson's disease who were already taking levodopa and other dopaminergic treatments were given 50 or 100 milligrams of safinamide per day or a placebo pill. Scientists tested participant's movement ability using the United Parkinson's disease rating scale that measures activities such as tremor, speech, behavior, mood and daily activities including swallowing, dressing and walking. A specific tool measuring severity of dyskinesia (DRS) was used in addition as primary efficacy endpoint.

At the start of the study, patients who took the 50 milligram dose of safinamide had an average score of 3.9 compared to a score of 3.4 for those taking a placebo pill. Patients who took the 100 milligram dose had an average score of 3.7.

After two years, researchers discovered in a post-hoc analysis that safinamide at 100 milligrams a day on top of taking levodopa reduced dyskines
'/>"/>

SOURCE American Academy of Neurology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
2. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
3. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
4. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
5. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
6. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
7. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
8. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
9. FDA Clears GeNO LLCs Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 2DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 3HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 2HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 3
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous ... collection of brown evening dresses for worldwide ... at discounted prices, up to 50% off. , ... they are carefully made according to most fashionable styles. ... also offers pretty accessories: wedding shoes, dancing shoes, sandals, ...
(Date:7/13/2014)... (PRWEB) July 14, 2014 MillionaireCasket.com is a ... manager, its excellent wood caskets are selling well in the ... of cherry caskets and launched a special offer ... the low prices, all the company’s cherry caskets are made ... is a must for people to show respect to the ...
(Date:7/13/2014)... and variations in the quality of care are the ... still varies widely between regions within Europe, according to ... to date, published in The Lancet Oncology . ... most cancers of the blood has increased over the ... new targeted drugs in the early 2000s such as ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3
... on Sunday became the first US city to banish trans ... uphill struggle in forcing some eateries to display calorie ... New York's 20,000 restaurants, the transition towards healthier cooking oils ... degree of reluctance. ,At the heart of the ...
... for superstition and marketing to come together: starry-eyed couples are ... concerts as well as the proclamation of the world's seven ... has a magic sacred side and the reputation of bringing ... an extra dose of good fortune. ,"Number 7 ...
... but it seems as though capitalism is bad for men's ... in mortality rates after the collapse of the Soviet Union. ... the Iron Curtain dropped by six years between 1991 and ... ,The degree to which men were affected depended upon ...
... for INVEGA(TM) (paliperidone prolonged release tablets), an ... schizophrenia. This once-daily medication is specifically ... ingredient in INVEGA - through the innovative ... INVEGA demonstrated significant efficacy as compared to ...
... germ cell tumour patients treated with platinum-based chemotherapy ... function and reproductive ability. ,The ... also found that despite having reproductive and sexual ... counterparts to be involved in meaningful, positive relationships. ...
... of Calgary in Alberta have shown that female mice tend ... male's urine, a discovery that outlines how chemical messages ... Samuel Weiss and his colleagues at the university looked at ... animals use to recognize and choose their mates, on the ...
Cached Medicine News:Health News:New York Bans Trans Fats in Restaurants 2Health News:New York Bans Trans Fats in Restaurants 3Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:Capitalism is Bad for Men's Health: Study 2Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 2Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 3Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 4Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 5Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3Health News:Male Pheromones Build Brain Cells in Female Mice 2
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Stainless steel disposable retinal MVR blade, 10 pcs / box....
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Refresh Contacts provides moisturizing relief from dryness and irritation associated with lens wear....
Medicine Products: